A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis
Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This Phase 3, open-label, triple arm study aims to evaluate the overall survival (OS) of
fotemustine versus the combination of ipilimumab and fotemustine or the combination of
Ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis.